{
    "id": 1168,
    "fullName": "KRAS G13X",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "KRAS G13X indicates any KRAS missense mutation that results in replacement of the glycine (G) at amino acid 13 by a different amino acid. KRAS codon 13 variants are hotspot mutations that often interfere with Ras GTPase activity, resulting in downstream pathway activation (PMID: 21993244, PMID: 22589270, PMID: 28666118).",
            "references": [
                {
                    "id": 2097,
                    "pubMedId": 22589270,
                    "title": "A comprehensive survey of Ras mutations in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22589270"
                },
                {
                    "id": 2102,
                    "pubMedId": 21993244,
                    "title": "RAS oncogenes: weaving a tumorigenic web.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21993244"
                },
                {
                    "id": 9843,
                    "pubMedId": 28666118,
                    "title": "RAS Proteins and Their Regulators in Human Disease.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28666118"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 3845,
        "geneSymbol": "KRAS",
        "terms": [
            "KRAS",
            "'C-K-RAS",
            "C-K-RAS",
            "c-Ki-ras",
            "c-Ki-ras2",
            "CFC2",
            "K-Ras",
            "K-Ras 2",
            "K-RAS2A",
            "K-RAS2B",
            "K-RAS4A",
            "K-RAS4B",
            "KI-RAS",
            "KRAS1",
            "KRAS2",
            "NS",
            "NS3",
            "OES",
            "RALD",
            "RASK2"
        ]
    },
    "variant": "G13X",
    "createDate": "07/27/2014",
    "updateDate": "11/12/2019",
    "referenceTranscriptCoordinates": {
        "id": 157175,
        "transcript": "NM_033360",
        "gDna": "chr12:g.25245346_25245348",
        "cDna": "c.37_39",
        "protein": "p.G13",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 18988,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BI-3406 inhibited MAPK signaling, resulted in growth inhibition of cancer cell lines harboring KRAS G13X mutations in culture and in cell line xenograft models (AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct 2019, Abstract PL06-01).",
            "molecularProfile": {
                "id": 1193,
                "profileName": "KRAS G13X"
            },
            "therapy": {
                "id": 8871,
                "therapyName": "BI-3406",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16631,
                    "pubMedId": null,
                    "title": "Discovery of BI-3406: a potent and selective SOS1:KRAS inhibitor opens a new approach for treating KRAS-driven tumors",
                    "url": "https://eventpilotadmin.com/web/planner.php?id=AACR19MT"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12578,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Vectibix (panitumumab) did not demonstrate efficacy in patients with metastatic colorectal cancer harboring KRAS mutations in codons 12 or 13 (PMID: 18316791; NCT00113763).",
            "molecularProfile": {
                "id": 1193,
                "profileName": "KRAS G13X"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 340,
                    "pubMedId": 18316791,
                    "title": "Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18316791"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17113,
            "approvalStatus": "FDA contraindicated",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab) treatment of colorectal cancer patients with KRAS exon 2, codon 13 mutations is contraindicated (FDA.gov).",
            "molecularProfile": {
                "id": 1193,
                "profileName": "KRAS G13X"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15480,
                    "pubMedId": null,
                    "title": "Vectibix (panitumumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125147"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15743,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, Salirasib was well tolerated in Japanese patients with advanced solid tumors (n=21), and while the median progression-free survival (PFS) in the study overall was 53 days, patients harboring mutations in codon G12 or G13 of Kras (n=4) had a median PFS of 227 days (PMID: 29992354).",
            "molecularProfile": {
                "id": 1193,
                "profileName": "KRAS G13X"
            },
            "therapy": {
                "id": 909,
                "therapyName": "Salirasib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13693,
                    "pubMedId": 29992354,
                    "title": "An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29992354"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1301,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, KRAS codon 12 or 13 mutations correlated with a lack of response to Iressa (gefitinib) in patients with lung adenocarcinoma (PMID: 15696205).",
            "molecularProfile": {
                "id": 1193,
                "profileName": "KRAS G13X"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 211,
                    "pubMedId": 15696205,
                    "title": "KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15696205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3266,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI did not have improved clinical benefit compared to FOLFIRI alone in patients with KRAS exon 2 mutant colorectal cancer (PMID: 26341920).",
            "molecularProfile": {
                "id": 1193,
                "profileName": "KRAS G13X"
            },
            "therapy": {
                "id": 3102,
                "therapyName": "Fluorouracil + Irinotecan + Oxaliplatin + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3703,
                    "pubMedId": 26341920,
                    "title": "Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26341920"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17099,
            "approvalStatus": "FDA contraindicated",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab) treatment of colorectal cancer patients with KRAS exon 2, codon 13 mutations is contraindicated (FDA.gov).",
            "molecularProfile": {
                "id": 1193,
                "profileName": "KRAS G13X"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15479,
                    "pubMedId": null,
                    "title": "Erbitux (cetuximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1440,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, sensitivity to Eloxatin (oxaliplatin) was increased in colorectal tumor cell lines carrying KRAS codon 12 or 13 mutations (PMID: 23209813).",
            "molecularProfile": {
                "id": 1193,
                "profileName": "KRAS G13X"
            },
            "therapy": {
                "id": 1104,
                "therapyName": "Oxaliplatin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1282,
                    "pubMedId": 23209813,
                    "title": "KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23209813"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3378,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a colorectal cancer patient harboring a PIK3CA G1049 mutation and KRAS mutations at codons 12 and 13 demonstrated stable disease when treated with a combination of Torisel (temsirolimus) and Avastin (bevacizumab) (PMID: 21216929).",
            "molecularProfile": {
                "id": 13305,
                "profileName": "KRAS G12X KRAS G13X PIK3CA mut"
            },
            "therapy": {
                "id": 3133,
                "therapyName": "Bevacizumab + Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3726,
                    "pubMedId": 21216929,
                    "title": "PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21216929"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1193,
            "profileName": "KRAS G13X",
            "profileTreatmentApproaches": [
                {
                    "id": 15812,
                    "name": "MEK2 Inhibitor",
                    "profileName": "KRAS G13X"
                },
                {
                    "id": 15806,
                    "name": "PIK3CA inhibitor",
                    "profileName": "KRAS G13X"
                },
                {
                    "id": 15808,
                    "name": "AZD4785",
                    "profileName": "KRAS G13X"
                },
                {
                    "id": 15809,
                    "name": "PI3K Inhibitor (Pan)",
                    "profileName": "KRAS G13X"
                },
                {
                    "id": 15807,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "KRAS G13X"
                },
                {
                    "id": 15810,
                    "name": "MEK1 Inhibitor",
                    "profileName": "KRAS G13X"
                },
                {
                    "id": 15811,
                    "name": "RAS Inhibitor (Pan)",
                    "profileName": "KRAS G13X"
                }
            ]
        },
        {
            "id": 13305,
            "profileName": "KRAS G12X KRAS G13X PIK3CA mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 157177,
            "transcript": "XM_011520653",
            "gDna": "chr12:g.25245346_25245348",
            "cDna": "c.37_39",
            "protein": "p.G13",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 157175,
            "transcript": "NM_033360",
            "gDna": "chr12:g.25245346_25245348",
            "cDna": "c.37_39",
            "protein": "p.G13",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 157176,
            "transcript": "XM_017019293",
            "gDna": "chr12:g.25245346_25245348",
            "cDna": "c.37_39",
            "protein": "p.G13",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 157174,
            "transcript": "NM_004985",
            "gDna": "chr12:g.25245346_25245348",
            "cDna": "c.37_39",
            "protein": "p.G13",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 157178,
            "transcript": "XM_006719069",
            "gDna": "chr12:g.25245346_25245348",
            "cDna": "c.37_39",
            "protein": "p.G13",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}